Clinical trial
A Phase I Trial of the Combination of Lenalidomide and Blinatumomab in Patients With Relapsed or Refractory Non-Hodgkins Lymphoma (NHL)
NCT02568553 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I Trial of the Combination of Lenalidomide and Blinatumomab in Patients With Relapsed or Refractory Non-Hodgkins Lymphoma (NHL)
- Lead sponsor
- National Cancer Institute (NCI)
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- November 15, 2016
- Completion date
- November 24, 2025
- Enrollment
- 35 (actual)
- Sites
- 24
Conditions
As the registry lists them; a condition with its own page is linked.
recurrent burkitt lymphoma, recurrent diffuse large b-cell lymphoma, recurrent grade 1 follicular lymphoma, recurrent grade 2 follicular lymphoma, recurrent grade 3 follicular lymphoma, recurrent grade 3a follicular lymphoma, recurrent grade 3b follicular lymphoma, recurrent gray-zone lymphoma, recurrent mantle cell lymphoma, recurrent marginal zone lymphoma, recurrent mediastinal lymphoma, recurrent non-hodgkin lymphoma, recurrent small lymphocytic lymphoma, refractory burkitt lymphoma, refractory diffuse large b-cell lymphoma, refractory follicular lymphoma, refractory grade 1 follicular lymphoma, refractory grade 2 follicular lymphoma, refractory grade 3 follicular lymphoma, refractory grade 3a follicular lymphoma, refractory gray-zone lymphoma, refractory mantle cell lymphoma, refractory marginal zone lymphoma, refractory mediastinal lymphoma, refractory non-hodgkin lymphoma, refractory small lymphocytic lymphoma